Cytoprotection in gastroesophageal reflux disease and prospects for the use of cytoprotective agents
Abstract
The analysis of publications is devoted to the problem of treatment and prevention of gastroesophageal reflux disease with the use of cytoprotectors. Special attention is paid to Gastrotop, the new complex of plant origin.
Gastrotop (Еrвоzета S.p.A, San Marino) is a new medication with cytoprotective action, containing Mucosave CG, a standardized complex of polysaccharides from the stems of Indian prickly pear (Opuntia ficus‑indica, 33.5%), leaves of European olive (Olea europaea, 24.0%); a mixture of sodium alginate and salts (sodium alginate — 50 mg, potassium bicarbonate — 10 mg, calcium carbonate — 10 mg), an extract of the leaves of Malva sylvestris L. 50 mg. Its action is aimed at the increasing of protection of esophageal and gastroduodenal mucosa from irritating effects of hydrochloric acid, pepsin, and the detergent effect of bile during reflux by means of formation of a strong mucoadhesive biofilm on the walls of the esophagus.
The authors present the results of a randomized, double‑blind, controlled clinical trial evaluating the efficacy and safety of a preparation based on alginate/sodium bicarbonate in combination with extracts obtained from Opuntia ficus indica and Olea europaea related to polyphenols on the dynamics of GERD symptoms. It has been established that Gastrotop is well tolerated and effective in controlling symptoms associated with mild GERD manifestations. The results demonstrated the perspective of administration of a standardized complex of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.